Table 1.
Baseline characteristics.
| Variables | No. (%), median [range] n = 223 |
p value | No. (%), median [range] n = 172 |
p value | ||
|---|---|---|---|---|---|---|
| High intensity chemotherapy | Low intensity chemotherapy | |||||
| With TKI (n = 94) |
Without TKI (n = 129) |
With TKI (n = 62) |
Without TKI (n = 110) |
|||
| Age, years | 52 [20–78] | 55 [17–82] | 0.02 | 71.5 [52–86] | 71 [21–89] | 0.69 |
| Male | 36 (38.3) | 60 (46.5) | 0.27 | 31 (50) | 65 (59) | 0.27 |
| WBC, ×109/L | 8.45 [0.5–378] | 14.2 [0.8–191] | 0.03 | 8 [0.2–164.5] | 11.7 [0.4–186.5] | 0.14 |
| LDH, IU × 10−3 | 1 [0.37–8.77] | 0.99 [0.37–11.15] | 0.46 | 0.98 [0.28–10.3] | 1.08 [0.23–42] | 0.41 |
| BM blasts, % | 54 [0–98] | 43 [0–99] | 0.50 | 26.5 [0–98] | 46 [0–98] | 0.38 |
| Diploid CG | 70 (74.5) | 87 (69) | 0.45 | 42 (75) | 75 (72.8) | 0.85 |
| Complex CG | 5 (5.3) | 5 (3.9) | 0.75 | 3 (5.1) | 7 (6.4) | >0.99 |
| ELN 2017 subgroup | ||||||
| 1 | 18 (19.2) | 14 (11) | 0.05 | 9 (14.5) | 17 (15.4) | 0.69 |
| 2 | 46 (48.9) | 82 (63.5) | 35 (56.5) | 66 (60) | ||
| 3 | 30 (31.9) | 30 (23.2) | 18 (29) | 25 (22.7) | ||
| FLT3-ITD size | 53 [8–195] | 53 [17–227] | 0.86 | 54 [7–207] | 45 [2–195] | 0.38 |
| FLT3-ITD ratio | 0.56 [0.01–2.46] | 0.35 [0.01–7.7] | 0.21 | 0.64 [0.01–2.56] | 0.32 [0.01–6.11] | 0.002 |
| FLT3-ITD number | ||||||
| 1 | 45 (47.8) | 104 (81.9) | <0.001 | 28 (45.2) | 77 (70) | <0.001 |
| 2 | 15 (15.9) | 15 (11.8) | 14 (22.6) | 22 (20) | ||
| 3 | 34 (36.2) | 8 (6.3) | 20 (32.3) | 11 (10) | ||
| FLT3 D835 | 6 (6.4) | 10 (7.7) | 0.80 | 9 (14.5) | 7 (6.4) | 0.10 |
| NPM1 | 45 (51.1) | 34 (45.3) | 0.53 | 32 (54.2) | 31 (39.3) | 0.09 |
| IDH1/2 | 16 (22.9) | 13 (26) | 0.83 | 13 (22.8) | 13 (22.8) | 0.40 |
| DNMT3A | 18 (28.1) | 9 (27.3) | >0.99 | 22 (44) | 3 (6.4) | <0.001 |
| No. co-mutations | ||||||
| 0 | 22 (23.7) | 66 (58.4) | <0.001 | 11 (18) | 53 (52) | <0.001 |
| 1 | 33 (35.5) | 29 (25.7) | 17 (27.9) | 25 (24.5) | ||
| 2 | 20 (21.5) | 15 (13.3) | 19 (31.2) | 19 (18.6) | ||
| ≥3 | 18 (19.4) | 3 (2.6) | 14 (22.9) | 5 (4.9) | ||
| Treatment regimen | ||||||
| Doublet | 32 (34) | 105 (81.4) | <0.001 | |||
| Triplet | 62 (66) | 24 (18.6) | ||||
| HMA-based | 51 (82.3) | 44 (40) | <0.001 | |||
| LDAC-based | 9 (14.5) | 49 (44.5) | ||||
| TKI | ||||||
| Quizartinib | 3 (3.2) | – | 13 (21) | – | ||
| Sorafenib | 91 (96.8) | – | 40 (64.5) | – | ||
| Midostaurin | – | – | 8 (12.9) | – | ||
| Axitinib | – | – | 1 (1.6) | – | ||
| AlloHSCT | 54 (57.5) | 43 (33.3) | <0.001 | 8 (13) | 9 (8.2) | 0.43 |